1090 related articles for article (PubMed ID: 31932844)
1. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
[TBL] [Abstract][Full Text] [Related]
2. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies.
Zucenka A; Pileckyte R; Trociukas I; Peceliunas V; Vaitekenaite V; Maneikis K; Davainis L; Zvirblis T; Stoskus M; Gineikiene E; Norvilas R; Dirse V; Surauciute A; Zucenkiene E; Griskevicius L
Eur J Haematol; 2021 Jan; 106(1):105-113. PubMed ID: 32997830
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
12. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
14. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA; Pollyea DA
Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax in acute myeloid leukemia - current and future directions.
Lachowiez C; DiNardo CD; Konopleva M
Leuk Lymphoma; 2020 Jun; 61(6):1313-1322. PubMed ID: 32031033
[TBL] [Abstract][Full Text] [Related]
17. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
Maiti A; Konopleva MY
Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M; Menghrajani K; Derkach A; Chan A; Xiao W; Glass J; King AC; Daniyan AF; Famulare C; Cuello BM; Horvat TZ; Abdel-Wahab O; Levine RL; Viny AD; Stein EM; Cai SF; Roshal M; Tallman MS; Goldberg AD
Blood Adv; 2021 Mar; 5(5):1552-1564. PubMed ID: 33687434
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
